A Phase 2 interventional study of dimebon in Alzheimer's Disease, sponsored by Medivation, Inc.. Terminated at 4 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2015-12-10.
Sponsored by Medivation, Inc. · Phase 2, Interventional, and Treatment
The purpose of this study is to assess the safety and efficacy of Dimebon in combination with donepezil (Aricept) in the treatment of Alzheimer's disease.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's enrollment of 50 is below the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Medivation, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
20 mg by mouth 3 times a day
Drug: dimebon
To assess the safety of Dimebon in combination with donepezil (Aricept)
Time frame: week 6, 9, 12, 26 and every 13 weeks thereafter until study discontinuation
This study is terminated, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medivation, Inc.